Trial Profile
Bivalirudin PCI Registry in HIT/HITTS Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary)
- Indications Embolism and thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome
- Focus Therapeutic Use
- Sponsors The Medicines Company
- 15 Oct 2020 Planned End Date changed from 1 Sep 2009 to 10 May 2010.
- 15 Oct 2020 Status changed from completed to withdrawn prior to enrolment as No patients were enrolled.
- 09 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.